Description: Cassava Sciences, Inc. develops drugs for nervous system disorders in the United States. It engages in developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Home Page: www.cassavasciences.com
SAVA Technical Analysis
7801 North Capital of Texas Highway
Austin,
TX
78731
United States
Phone:
512 501 2444
Officers
| Name | Title |
|---|---|
| Mr. Remi Barbier | Founder, Chairman, Pres & CEO |
| Mr. Eric J. Schoen | Chief Financial Officer |
| Dr. Nadav Friedmann M.D., Ph.D. | Chief Medical Officer & Director |
| Dr. James W. Kupiec M.D. | Chief Clinical Devel. Officer |
| Dr. George Thornton | Sr. VP of Technology |
| Mr. R. Christopher Cook | Sr. VP & Gen. Counsel |
| Mr. Michael Zamloot | Sr. VP of Technical Operations |
| Dr. Michael Marsman Pharm.D. | Sr. VP of Regulatory Affairs |
| Dr. Lindsay H. Burns Ph.D. | Sr. VP of Neuroscience |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 56.4972 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.2662 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2000-07-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |